Literature DB >> 23398474

Phenotypic susceptibility to antiretrovirals among clades C, F, and B/F recombinant antiretroviral-naive HIV type 1 strains.

Maria Cecilia A Sucupira1, Patricia Munerato, Jussara Silveira, André F Santos, Luiz Mário Janini, Marcelo A Soares, Ricardo Sobhie Diaz.   

Abstract

To evaluate antiretroviral phenotypic susceptibility of wild-type HIV-1 strains circulating in Brazil, samples from antiretroviral-naive individuals infected with subtypes C (n=16), F (n=9), or B/F (n=7), where reverse transcriptase is B and protease is F, were phenotyped using the Antivirogram Assay (Virco, Mechelen, Belgium). Reduced susceptibility to protease inhibitors (PIs) was observed in one C and three F isolates. None of these samples had any known PI resistance mutations. The phenotypic fold change to one PI was above the biological cut-off in three of 96 (3.1%) clade F phenotypic determinations and in one of 96 (1.0%) clade C. Phenotypic resistance to at least one nucleoside reverse transcriptase inhibitor (NRTI) was found for two B/F, four C, and three F isolates. The phenotypic fold change in susceptibility to NRTIs was above the cut-off value in nine of 111 (8.1%) clade C determinations, as compared to three of 63 (4.8%) for clade F and two of 49 (4.1%) for clade B. The phenotypic fold change to non-NRTI (NNRTI) was above the cut-off in seven of 32 (21.9%) of C isolates determinations, whereas none of the F isolates had a decrease of susceptibility. Only two of the 16 C samples had a known NNRTI resistance mutation. The NNRTI fold change was above the cut-off value in three of 14 (21.4%) phenotypic determinations of Brazilian B/F recombinants, representing clade B reverse transcriptase. NNRTI susceptibility should be better investigated in clade C and B/F recombinants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23398474     DOI: 10.1089/AID.2012.0259

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

1.  Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil.

Authors:  Sergio Monteiro de Almeida; Clea Elisa Ribeiro; Ana Paula de Pereira; Jayraan Badiee; Mariana Cherner; Davey Smith; Ingrid Maich; Sonia Mara Raboni; Indianara Rotta; Francisco Jaime Barbosa; Robert K Heaton; Anya Umlauf; Ronald J Ellis
Journal:  J Neurovirol       Date:  2013-11-26       Impact factor: 2.643

2.  Brazilian network for HIV Drug Resistance Surveillance (HIV-BresNet): a survey of treatment-naive individuals.

Authors:  Monica B Arruda; Lídia T Boullosa; Cynthia C Cardoso; Carolina M da Costa; Carlos Rb Alves; Shirlene Ts de Lima; Helena T Kaminski; Agdemir W Aleixo; Ana Op Esposito; Ana Ms Cavalcanti; Maristela Riedel; José C Couto-Fernandez; Selma B Ferreira; Ivi Cm de Oliveira; Loreci E Portal; Hilda Hc Wolf; Sandra B Fernandes; Maria I de M C Pardini; Manoel Vc Feiteiro; Fernanda M Tolentino; Ricardo S Diaz; Giselle Isl Lopes; Roberta Bl Francisco; Nazle Mc Véras; Ana F Pires; Miriam Franchini; Fábio Mesquita; Amilcar Tanuri
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

3.  Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating antiretroviral therapy in Brazil: a surveillance study using dried blood spots.

Authors:  Celina M P de Moraes Soares; Tania R C Vergara; Carlos Brites; Jose D U Brito; Gorki Grinberg; Marcos M Caseiro; Carlos Correa; Theodoro A Suffert; Flavio R Pereira; Michelle Camargo; Luiz M Janini; Shirley Komninakis; Maria C A Sucupira; Ricardo S Diaz
Journal:  J Int AIDS Soc       Date:  2014-09-22       Impact factor: 5.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.